4
|
Vecht C, Duran-Peña A, Houillier C, Durand T, Capelle L, Huberfeld G. Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations. J Neurooncol 2017; 133:603-607. [PMID: 28492978 DOI: 10.1007/s11060-017-2473-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2017] [Accepted: 05/07/2017] [Indexed: 11/27/2022]
Abstract
Drug-resistant epilepsy (DRE) occurs commonly in gliomas, possibly due to a shared mechanism of AMPA-activation involving both seizure activity and tumor growth. We tested the AMPA-receptor blocker perampanel (PER) in patients with DRE in low- and high-grade gliomas. Seizure response was defined as 50% drop in seizure frequency or as seizure-freedom. Cognitive function was examined by computerized test on cognitive speed (CTCS), which is sensitive to the type of cognitive dysfunction associated with epilepsy and use of anticonvulsants. Treatment policy included reduction of dose or discontinuation of one or more concurrent AEDs, once a seizure-free response was observed. Twelve patients were included patients, median age 41 years, 9 men versus 3 women and 6 months median duration of follow-up. An objective seizure response (75%) was observed in 9 (75%) out of 12 patients: 50%-seizure response in 3, seizure-freedom in 6, which is plainly more than seen with other types of DRE. Side-effects occurred in six patients. Cognitive function as examined by CTCS improved in six out of eight associated withlowering of concurrent AEDs. The final median dose of PER was 8 mg (varying between 2 and 12 mg). These results of an objective seizure response in 9 (75%) out of 12 patients treated by PER in DRE may be interpreted as a surrogate-marker of tumor response secondary to AMPA blockade, advancing confirmation by MR imaging. These results warrant further study of PER on tumor activity in gliomas.
Collapse
Affiliation(s)
- Charles Vecht
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France. .,Service Neurologie Mazarin, CHU Pitié-Salpêtrière, Paris, 47 Bld. de l´Hopital, 75651, PARIS CEDEX 13, France.
| | - Alberto Duran-Peña
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Caroline Houillier
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Thomas Durand
- Department of Neurology Mazarin, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Laurent Capelle
- Neurosurgery Babinski, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| | - Gilles Huberfeld
- Pitié-Salpêtrière Hospital, and Laboratory of Neurophysiology, Université Pierre et Marie Curie, INSERM U1129, 75015, Paris, France
| |
Collapse
|
6
|
Durand T, Jacob S, Lebouil L, Douzane H, Lestaevel P, Rahimian A, Psimaras D, Feuvret L, Leclercq D, Brochet B, Tamarat R, Milliat F, Benderitter M, Vayatis N, Noël G, Hoang-Xuan K, Delattre JY, Ricard D, Bernier MO. EpiBrainRad: an epidemiologic study of the neurotoxicity induced by radiotherapy in high grade glioma patients. BMC Neurol 2015; 15:261. [PMID: 26684198 PMCID: PMC4683733 DOI: 10.1186/s12883-015-0519-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2015] [Accepted: 12/11/2015] [Indexed: 12/02/2022] Open
Abstract
Background Radiotherapy is one of the most important treatments of primary and metastatic brain tumors. Unfortunately, it can involve moderate to severe complications among which leukoencephalopathy is very frequent and implies cognitive deficits such as memory, attention and executive dysfunctions. However, the incidence of this complication is not well established and the risk factors and process are poorly understood. The main objective of the study is to improve knowledge on radio-induced leukoencephalopathy based on pluridisciplinar approaches combining cognitive, biologic, imagery and dosimetric investigations. Method/Design The EpiBrainRad study is a prospective cohort study including newly diagnosed high grade gliomas patients treated by radiotherapy and concomitant-adjuvant temozolomide chemotherapy. Patients are included between their surgery and first day of radio-chemotherapy, and the follow-up lasts for 3 years after treatment. Cognitive functioning assessments, specific blood biomarkers measures and magnetic resonance imagery are performed at different moment during the follow-up, and a specific dosimetric assessment of organs involved in the beam fields is performed. Firstly, leukoencephalopathy incidence rate will be estimated in this population. Secondly, correlations between cognitive impairments and dosimetry, biomarkers ranges and anomalies on imagery will be analyzed in order to better understand the onset and evolution of cognitive decrement associated with radiotherapy. Furthermore, a new cognitive test, quickly and easily performed, will be studied to determine its sensibility to detect leukoencephalopathy decrement. Discussion With an original multidisciplinary approach, the EpiBrainRad study aims to improve knowledge on radio-induced leukoencephalopathy in order to improve its early diagnosis and prevention. The main challenge is to preserve quality-of-life after cancer treatments which imply to study the incidence of radiation-induced complications and their associated risk factors. Trial Registration NCT02544178
Collapse
Affiliation(s)
- Thomas Durand
- UMR CNRS 8257 SSA MD4 Cognition and Action Group, 45 rue des Saints Pères, 75270, Paris CEDEX 06, France. .,Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Sophie Jacob
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, 31 avenue de la Division Leclerc, 92260, Fontenay aux Roses, France.
| | - Laura Lebouil
- Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Hassen Douzane
- Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Philippe Lestaevel
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, 31 avenue de la Division Leclerc, 92260, Fontenay aux Roses, France.
| | - Amithys Rahimian
- Institut du Cerveau et de la Moelle, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Dimitri Psimaras
- Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Loïc Feuvret
- Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Delphine Leclercq
- Unité de neuroradiologie diagnostique et fonctionnelle, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Bruno Brochet
- Service de Neurologie, groupe hôspitalier Pellegrin, place Amélie Raba-Léon, 33076, Bordeaux, France.
| | - Radia Tamarat
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, 31 avenue de la Division Leclerc, 92260, Fontenay aux Roses, France.
| | - Fabien Milliat
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, 31 avenue de la Division Leclerc, 92260, Fontenay aux Roses, France.
| | - Marc Benderitter
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, 31 avenue de la Division Leclerc, 92260, Fontenay aux Roses, France.
| | - Nicolas Vayatis
- UMR CNRS 8536 Centre de mathématiques et de leurs applications, ENS Cachan, 61 avenue du président Wilson, 94235, Cachan CEDEX, France.
| | - Georges Noël
- Département de radiothérapie, centre de lutte contre le cancer Paul Strauss, 3 rue de la porte de l'hôpital, 67065, Strasbourg CEDEX, France.
| | - Khê Hoang-Xuan
- Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Jean-Yves Delattre
- Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France.
| | - Damien Ricard
- UMR CNRS 8257 SSA MD4 Cognition and Action Group, 45 rue des Saints Pères, 75270, Paris CEDEX 06, France. .,Service de neurologie Mazarin, hôpital de la Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75013, Paris, France. .,Service de neurologie, hôpital d'instruction des armées du Val-de-Grace, 71 boulevard de Port-Royal, 75005, Paris, France.
| | - Marie-Odile Bernier
- Institut de Radioprotection et de Sûreté Nucléaire (IRSN), PRP-HOM, SRBE, 31 avenue de la Division Leclerc, 92260, Fontenay aux Roses, France.
| |
Collapse
|
7
|
Aboukais R, Zairi F, Lejeune JP, Le Rhun E, Vermandel M, Blond S, Devos P, Reyns N. Grade 2 meningioma and radiosurgery. J Neurosurg 2015; 122:1157-62. [DOI: 10.3171/2014.9.jns14233] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
OBJECT
World Health Organization Grade 2 meningiomas are aggressive tumors associated with a high recurrence rate leading to repeated surgical procedures, which can seriously worsen a patient's neurological status. Although radiosurgery is an increasingly popular technique, its role in the management of Grade 2 meningiomas has yet to be defined. In this study the authors aimed to evaluate radiosurgery in achieving control of proven tumor progression occurring after resection of Grade 2 meningioma.
METHODS
This retrospective study included consecutive patients who, between 2000 and 2012, had undergone radiosurgery for radiologically proven progression of a previously surgically treated Grade 2 meningioma.
RESULTS
Twenty-seven patients were eligible for analysis. There were 9 men and 18 women with a mean age of 59 years. The mean radiation dose was 15.2 Gy (range 12–21 Gy), and the mean target volume was 5.4 cm3 (range 0.194–14.2 cm3). Thirty-four radiosurgical procedures were performed in the 27 patients. The mean progression-free survival after radiosurgery was 32.4 months among those with progression in a target irradiated volume and 26.4 months among those with progression in any intracranial meninges. With a mean follow-up of 56.4 months (range 12–108 months), the 12-, 24-, and 36-month actuarial local control rates for all patients were 75%, 52%, and 40%, respectively, and the regional control rates were 75%, 48%, and 33%. A single case of transient hemiparesis completely resolved without sequelae.
CONCLUSIONS
Radiosurgery appears to be a safe and effective treatment for the local control of delayed progression after resection of a Grade 2 meningioma. Higher radiation doses similar to those applied for malignant tumors should be recommended when possible.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Patrick Devos
- 3Statistics, Lille University Hospital, Lille, France
| | | |
Collapse
|
9
|
Bellefqih S, Mezouri I, Khalil J, Bazine A, Diakité A, El Kacimi H, Kebdani T, Benjaafar N. [Primary central nervous lymphoma: what is the role for radiotherapy?]. Cancer Radiother 2014; 18:685-92. [PMID: 25451676 DOI: 10.1016/j.canrad.2014.06.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2014] [Revised: 05/23/2014] [Accepted: 06/06/2014] [Indexed: 10/24/2022]
Abstract
Primary central nervous system lymphoma is a rare extranodal form of non-Hodgkin lymphoma with an aggressive course and unsatisfactory outcome. Historically, whole-brain radiotherapy was the sole treatment for patients with primary central nervous system lymphoma, with high response rates but typically, this did not result in long-lasting remissions. The addition of high-dose methotrexate-based chemotherapy regimens to whole-brain radiotherapy has significantly improved patients' outcome, but has resulted in a higher incidence of late neurotoxicity, particularly in elderly patients. To date, the role of consolidation radiotherapy is controversial, and some investigators have developed alternative strategies aiming at avoiding immediate irradiation or using a reduced radiotherapy dose to the whole-brain with promising results.
Collapse
Affiliation(s)
- S Bellefqih
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc.
| | - I Mezouri
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| | - J Khalil
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| | - A Bazine
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| | - A Diakité
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| | - H El Kacimi
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| | - T Kebdani
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| | - N Benjaafar
- Service de radiothérapie, Institut national d'oncologie, avenue Allal El-Fassi, 10100 Rabat, Maroc; Université Mohammed-V Souissi, 10100 Rabat, Maroc
| |
Collapse
|